Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$62.0 - $79.01 $67.7 Million - $86.3 Million
-1,091,800 Reduced 92.17%
92,800 $6.77 Million
Q2 2024

Aug 14, 2024

BUY
$22.0 - $69.71 $25.3 Million - $80.1 Million
1,148,800 Added 3208.94%
1,184,600 $79.4 Million
Q1 2024

May 15, 2024

BUY
$25.72 - $29.94 $920,776 - $1.07 Million
35,800 New
35,800 $971,000
Q3 2023

Nov 14, 2023

BUY
$19.86 - $26.93 $486,570 - $659,785
24,500 Added 27.84%
112,500 $2.84 Million
Q2 2023

Aug 14, 2023

SELL
$16.44 - $21.1 $328,800 - $422,000
-20,000 Reduced 18.52%
88,000 $1.86 Million
Q1 2023

May 15, 2023

BUY
$16.26 - $21.73 $1.32 Million - $1.76 Million
81,000 Added 300.0%
108,000 $1.84 Million
Q4 2022

Feb 14, 2023

BUY
$16.98 - $23.15 $458,460 - $625,050
27,000 New
27,000 $539,000
Q1 2022

May 13, 2022

BUY
$20.42 - $28.13 $612,600 - $843,900
30,000 New
30,000 $705,000
Q4 2021

Feb 11, 2022

SELL
$25.89 - $33.45 $2.33 Million - $3.01 Million
-90,000 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$22.46 - $29.47 $673,800 - $884,100
30,000 Added 50.0%
90,000 $2.48 Million
Q2 2021

Aug 16, 2021

BUY
$24.17 - $36.01 $563,161 - $839,033
23,300 Added 63.49%
60,000 $1.71 Million
Q3 2020

Nov 16, 2020

BUY
$26.0 - $34.5 $954,200 - $1.27 Million
36,700 New
36,700 $1.18 Million
Q2 2020

Aug 14, 2020

SELL
$14.11 - $29.42 $203,184 - $423,648
-14,400 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$13.63 - $33.98 $92,684 - $231,063
6,800 Added 89.47%
14,400 $231,000
Q4 2019

Feb 13, 2020

SELL
$16.12 - $24.98 $441,688 - $684,452
-27,400 Reduced 78.29%
7,600 $181,000
Q3 2019

Nov 14, 2019

BUY
$15.49 - $25.78 $77,450 - $128,900
5,000 Added 16.67%
35,000 $617,000
Q1 2019

May 14, 2019

BUY
$13.91 - $31.15 $417,300 - $934,500
30,000 New
30,000 $872,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.